Nano-drug delivery system capable of entering brain through nose and targeting central nervous system as well as preparation method and application of nano-drug delivery system

Through lectin-coupled liposome nanoparticle technology, the biomacromolecular drug delivery barriers of the nasal pathway are broken through, efficient and accurate targeted delivery of the central nervous system is achieved, and the problem of low drug delivery efficiency of nasal pathway is solved.

CN119074944AActive Publication Date: 2024-12-06TAIYI LIFE TECH (NINGBO) CO LTD

Patent Information

Application Number
CN202411123364.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-12-06
Estimated Expiration
2044-08-15

AI Technical Summary

Technical Problem

The prior art is difficult to effectively deliver biomacromolecular drugs to the central nervous system through the nasal pathway, which is limited by the nasal mucosa epithelial pathway, resulting in low drug absorption efficiency, poor targeting, and difficulty in prolonging the adhesion time in the nasal mucosa and delivery in the central nervous system. ability.

Method used

Using lectin-coupled liposome nanoparticles (LNP) technology, by coupling lectin with specific components of liposome nanoparticles, the specific binding of fucose receptors is used to break through blood The brain barrier improves the adhesion time and adsorption capacity of drug nanomaterials in the nasal mucosa, achieving efficient delivery.

Benefits of technology

It significantly improves the targeting efficiency and delivery efficiency of biomacromolecular drugs, can accurately deliver drugs to the central nervous system, avoid drugs passing through the blood-brain barrier, prolong the retention time of drugs in the nasal cavity, and improves the delivery efficiency of nano drug delivery systems.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074944A_ABST
    Figure CN119074944A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine, and particularly discloses a nano-drug delivery system entering brain through nose and targeting central nervous and a preparation method and application thereof. The nano-drug delivery system capable of entering the brain through the nose and targeting the central nervous system comprises a biological treatment drug and lectin coupled liposome nano-particles wrapping the surface of the biological treatment drug, the biological treatment medicine is mRNA (messenger ribonucleic acid) coded biological macromolecules; the lectin is AAL, and the raw materials of the lipidosome nanoparticles comprise SM102, DSPC (Distearoyl Pyrrolidone), cholesterol, DMG-pSar25 and DSPE-PEG-MAL (Distearoyl Pyrrolidone-Polyethylene Glycol). According to the invention, AAL and LNP with specific components are coupled, so that specific recognition and binding with receptor fucose of target cells are realized, nano-materials are helped to be endocytosed through olfactory mucosa and delivered to the brain through a nasal-brain pathway, biological treatment drugs are delivered in a targeted manner, the blood-brain barrier is broken through, and the targeting efficiency and nasal delivery efficiency are remarkably improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to a nano drug delivery system for targeting the central nervous system via the nose and the brain, and a preparation method and application thereof. Background Art

[0002] There are huge challenges in drug development for degenerative diseases of the central nervous system, and an important reason for this is the existence of the blood-brain barrier (BBB). The blood-brain barrier is a cell complex with extremely low permeability between the blood and the neural tissue of the central nervous system. It has the characteristics of tight junctions. In addition, the presence of transporters and metabolic enzymes makes it difficult for about 98% of chemical drugs and almost 100% of macromolecular drugs (including protein peptides and gene drugs) to enter the brain to reach therapeutic concentrations. Drug delivery strategies for the central nervous system can be achieved through several routes of administration: systemic administration (such as intravenous injection) and invasive local administration (such as intrathecal injection and intraparenchymal administration). Systemic administration is an invasive method, and intravenous injection provides a minimally invasive opportunity for drugs to enter the brain, but this requires passing through the blood-brain barrier. Local or non-systemic routes of administration are also usually invasive. Currently, one strategy for non-invasive methods is administration through the nasal route.

[0003] Intranasal administration can deliver therapeutic drugs to the brain through the olfactory region of the nose, bypassing the blood-brain barrier. It has the characteristics of easy use, rapid absorption and onset of effect, high bioavailability, non-invasive and convenient administration, low damage to the body, avoiding liver metabolism and high patient compliance. The olfactory region of the nose is located at the top of the nasal cavity and is composed of the olfactory mucosa, lamina propria and olfactory bulb. As the only part of the central nervous system directly exposed to the external environment, the olfactory region of the nose is considered to be the most direct and fastest way for drugs to bypass the blood-brain barrier and enter the cerebrospinal fluid. Therefore, the nasal drug delivery system can deliver drugs directly to brain tissue via the nose-brain pathway. Based on the special anatomical connection between the nasal cavity and the brain, the drug transport pathway from the nose to the brain can be divided into three parts: the olfactory nerve pathway, the trigeminal nerve pathway and the blood circulation pathway. When the drug reaches the olfactory area, it can be transported into the brain via the intraneuronal pathway: the drug interacts with the nerve endings of the olfactory receptor neurons, passes through the cribriform plate along the axonal nerve bundles of the olfactory neurons to reach the olfactory bulb, and then diffuses into the interstitial fluid, cerebrospinal fluid and brain tissue. Compared with the slower transport pathway within olfactory neurons, in the extraneuronal transport pathway, drugs can be rapidly transported to different areas of the brain through tight junctions between supporting cells or channels between olfactory neurons and supporting cells. Once the drug diffuses to the trigeminal nerve branches in the olfactory and respiratory areas, it can be transported along the intra-neuronal axonal pathway and transported through the nose via the trigeminal nerve pathway. The blood circulation pathway is an indirect route for drugs to enter the brain through the nose. After nasal administration, the drug can be absorbed into the systemic blood circulation through the abundant capillaries under the nasal mucosa, and then cross the blood-brain barrier with the help of blood circulation to enter the central nervous system.

[0004] Currently, in the research of nano drug delivery systems, the main methods to bypass the blood-brain barrier are to use surfactants or nanoparticle encapsulation to enhance delivery. Nanostructured lipids (LNP), nanoemulsions and chitosan coating can be used to change the surface properties of nanoparticles to improve delivery to the brain; degradable polymer materials such as polylactic acid, polyglycolic acid, PLGA and polysebacic anhydride can encapsulate and increase the stability of drugs; brain-targeted uptake and delivery can be further achieved through the functionalization of cell-penetrating peptides and proteins.

[0005] However, there is no precedent for using nanoliposome particle carriers for intranasal administration. The nasal drug delivery system is limited by the nasal surface area and the characteristics of the nasal mucosa, which weakens the effective absorption of the drug. When delivering biologics, mucociliary clearance is a major challenge, and biological drugs are much larger than traditional small molecule drugs and have low membrane permeability, making it difficult to achieve effective absorption or prolong the therapeutic effect. Further research is still needed to open up the nasal mucosal epithelial pathway, effectively improve the nasal delivery efficiency of the nasal drug delivery system, target the best treatment area, prevent penetration into the lungs, avoid irritating the nasal mucosa, ensure sufficient retention time, improve the ability of liposome nanoparticles to adsorb to the nasal mucosa, and improve their internalization efficiency. Summary of the invention

[0006] In view of the above problems, the present invention provides a nano drug delivery system for central nervous system targeted via the nose and brain, as well as a preparation method and application thereof. The present invention innovatively utilizes liposome nanoparticle (LNP) technology and bioconjugation technology to open up the nasal mucosal epithelial pathway, thereby being able to efficiently and accurately deliver biomacromolecule drugs into the central nervous system, achieve the delivery of loaded drugs via the nose and brain, and significantly improve the attachment time, adsorption capacity and delivery capacity of drug nanomaterials in the nasal mucosa to the central nervous system.

[0007] In order to solve the above technical problems, the present invention adopts the following technical solutions: In a first aspect, the present invention provides a nano drug delivery system for central nervous system targeting via the nose and brain, comprising a biotherapeutic drug and lectin-coupled liposome nanoparticles, wherein the lectin-coupled liposome nanoparticles are coated on the surface of the biotherapeutic drug; The biological therapeutic drug is a biological macromolecule encoded by mRNA; the lectin in the lectin-coupled liposome nanoparticles is a lectin from Dictyosporum aurantiacum, and the raw materials of the liposome nanoparticles include SM102, DSPC, cholesterol, DMG-pSar25 and phospholipid polyethylene glycol maleimide.

[0008] It should be noted that SM102 represents an ionizable amino lipid, with the structural formula shown in Formula 1; DSPC represents a liposome compound, with the structural formula shown in Formula 2; the structural formula of cholesterol is shown in Formula 3; and DMG-pSar25 represents a polymer polyethylene glycol (PEG) derivative, with the structural formula shown in Formula 4.

[0009]

[0010] Formula 1

[0011] Formula 2

[0012] Formula 3

[0013] Formula 4 Compared with the prior art, the nano drug delivery system for central nervous system targeted via the nose and brain provided by the present invention couples AAL and liposome nanoparticles (LNP) of specific components, thereby specifically recognizing and binding to the receptor of target cells, fucose, to deliver biological therapeutic drugs in a targeted manner, break through the blood-brain barrier, and significantly improve the targeting efficiency and nasal delivery efficiency.

[0014] The present invention pioneered the use of liposome nanoparticle technology and bioconjugation technology to open up the nasal passage to the brain, thereby enabling efficient and accurate delivery of biomacromolecule drugs into the central nervous system. LNP-encapsulated mRNA delivery is used to deliver nucleic acids (such as mRNA) to cells. LNP is a small spherical particle composed of a lipid bilayer and a hydrophobic core, containing ionizable lipids, phospholipids, cholesterol, and lipid-anchored PEG as excipients, which contribute to the structural integrity, stability, and intracellular delivery of mRNA in LNP. mRNA is encapsulated in the hydrophobic core to prevent it from degradation in the blood. The present invention couples AAL with LNP for the first time, and uses phospholipid polyethylene glycol maleimide (DSPE-PEG-MAL) to modify LNP to facilitate the coupling of LNP with AAL. The lectin AAL of orange peel fungus is selected as a ligand. AAL contains up to 5 fucose binding sites, so it has a wider range of specific binding with the specific receptor fucose of nasal mucosal cells. It is designed to target specific cells, which significantly improves the attachment time and adsorption capacity of drug-loaded nanomaterials on the nasal mucosa, helps the nanomaterials to be internalized through the olfactory mucosa, and delivered to the brain through the nose-brain pathway without passing through the blood-brain barrier, thereby improving the delivery efficiency of the nano drug delivery system.

[0015] It should be noted that the present invention does not limit the specific type of biological therapeutic drugs, and any biological therapeutic agent that can target the cerebral cortex is applicable to the present invention, such as BDNF, Klotho, etc.

[0016] Preferably, the molar ratio of the SM102, the DSPC, the cholesterol, the DMG-pSar25 and the phospholipid polyethylene glycol maleimide is (45-50):(10-15):(38-40):(1-2):(0.3-0.7).

[0017] In the present invention, the amount of DSPE-PEG-MAL used is only about 0.3% to 0.7% of the molar amount of LNP, which can ensure that AAL is subsequently coupled to LNP, and then can be specifically combined with fucose, thereby improving the attachment time and adsorption capacity of the nano drug delivery system for central nervous system targeted via the nose to the brain on the nasal mucosa, and ensuring that the biotherapeutic drug has a higher delivery efficiency.

[0018] Preferably, the molar ratio of the nitrogen element in the ionizable cationic lipid of the liposome nanoparticle to the phosphorus element in the mRNA of the biotherapeutic drug is 4:1-8:1, more preferably 5:1-7:1.

[0019] The present invention controls the loading amount of the biotherapeutic drug by controlling the nitrogen-phosphorus ratio, so that the encapsulation rate of the mRNA of the biotherapeutic drug reaches the highest, thereby improving the targeting efficiency. If the nitrogen-phosphorus ratio is too low, the encapsulation rate of the mRNA of the biotherapeutic drug is reduced; if the nitrogen-phosphorus ratio is too high, LNP cavitation will occur, and the loading amount of the biotherapeutic drug will be reduced.

[0020] Preferably, the mass ratio of the sum of the mass of the liposome nanoparticles and the biotherapeutic drug to the mass of the lectin is 0.8:1 to 1.2:1.

[0021] The present invention can further improve the specific binding ability with fucose on nasal mucosal cells by controlling the dosage of lectin, further improve the attachment time and adsorption ability of the nano drug delivery system targeting the central nervous system through the nose to the brain on the nasal mucosa, thereby further improving the delivery efficiency of the nano drug delivery system.

[0022] Preferably, the particle size of the nano drug delivery system for central nervous system targeting via the nose to the brain is 70nm to 200nm.

[0023] In a second aspect, the present invention provides a method for preparing a nano drug delivery system for targeting the central nervous system via the nose and brain, comprising the following steps: S1, Assembly of liposomal nanoparticles with biotherapeutic drugs: S1-1, weighing each component according to the raw material ratio, dissolving SM102, DSPC, cholesterol, DMG-pSar25 and phospholipid polyethylene glycol maleimide in a first solvent to obtain a first mixed system; dissolving the biomacromolecule encoded by the mRNA in a second solvent to obtain a second mixed system; S1-2, adding the first mixed system and the second mixed system into a microfluidic mixer, removing the first solvent, and then dissolving in a third solvent to obtain an mRNA@LNP solution; S2, preparation of thiolated Dictyosporium aurantium agglutinin: The Dictyostelium aurantium agglutinin solution is mixed with the S-acetylthioacetic acid N-hydroxysuccinimide ester solution to carry out an amide reaction; the obtained reaction solution is mixed with the hydroxylamine hydrochloride solution to carry out a deacetamide reaction to obtain a thiolated Dictyostelium aurantium agglutinin solution; S3, coupling of thiolated Dictyosporium aurantium lectin with mRNA@LNP: The mRNA@LNP solution and the thiolated Dictyosporium aurantium lectin solution are mixed to carry out a coupling reaction, thereby obtaining a nano drug delivery system that targets the central nervous system through the nose and into the brain.

[0024] It should be noted that there is no order between S1 and S2. The present invention does not make any special requirements for the preparation of the biomacromolecule encoded by mRNA, and conventional methods in the art can be used.

[0025] The invention provides a method for preparing a nano drug delivery system for brain administration targeting the central nervous system through the nose. The method comprises the following steps: assembling biomacromolecules encoded by mRNA with liposomes by adopting microfluidic technology to obtain an mRNA@LNP solution in which a biotherapeutic drug is encapsulated in LNP; modifying LNP by adopting DSPE-PEG-MAL to introduce a maleimide group into four original lipids of LNP, and modifying AAL by adopting S-acetylthioglycolic acid N-hydroxysuccinimide ester (SATA) to introduce a thiol group (forming AAL-SH); coupling LNP with AAL by forming a thioether bond by a thiol-maleimide reaction; and adding AAL to mRNA@LNP to obtain a nano drug delivery system for brain administration targeting the central nervous system through the nose and the nose coupled with AAL.

[0026] Preferably, in S1-1, the first solvent is ethanol.

[0027] The present invention does not impose any limitation on the amount of ethanol used, as long as it can completely dissolve the above lipids.

[0028] For example, in S1-1, SM102, DSPC, cholesterol, DMG-pSar25 and DSPE-PEG-MAL are first dissolved in a first solvent, respectively, and then the five mixed solutions are mixed to obtain a first mixed system.

[0029] Preferably, in S1-1, the second solvent is a sodium acetate solution with a pH of 3.5 to 4.5 and a concentration of 45 mM to 55 mM.

[0030] Preferably, in S1-1, the volume ratio of the biomacromolecule encoded by the mRNA and the second solvent is 0.9:1~1.1:1.

[0031] Preferably, in S1-2, the volume ratio of the first mixed system to the second mixed system is 1:2.5~1:3.5.

[0032] In the example, S1-2, the microfluidic mixer is NanoAssemblr ® Ignite+™ (PrecisionNanosystems) mixer.

[0033] The present invention does not limit the method for removing the first solvent in S1-2, and conventional means in the art may be used.

[0034] Preferably, in S1-2, the third solvent is a mixed solution of 12mM~18mM Tris-HCl and 12mM~18mM sodium acetate.

[0035] For example, S1-2 includes the following steps: The first mixed system and the second mixed system were added to the microfluidic mixer, the program of the microfluidic mixer was set (FRR=3, TFR=12mL / min), the NxGEN microfluidic chip was inserted, the syringe was tightened, and the LNP microfluidic preparation was performed to obtain mRNA@LNP; The obtained mRNA@LNP was diluted with a third solvent having a volume 25 times that of the mRNA@LNP, and then ultrafiltration was performed to replace the liquid. After the replacement liquid was concentrated to the target volume, 0.2 μm sterilization filtration was performed to obtain the mRNA@LNP solution.

[0036] Preferably, in S1-2, the concentration of the mRNA@LNP solution is 450ng / μL~500ng / μL.

[0037] The present invention uses microfluidic technology to assemble biomacromolecules encoded by mRNA with liposomes, assembles a specific amount of liposomes and mRNA through a specific first solvent and a second solvent, and finally dissolves in a specific third solvent to obtain an mRNA@LNP solution. The present invention improves the encapsulation efficiency of mRNA of biotherapeutic drugs by controlling various conditions in microfluidic technology, thereby improving the delivery efficiency of the nano drug delivery system.

[0038] Preferably, in S2, the solvent of the Dictyostelium aurantium agglutinin solution is a fourth solvent, and the fourth solvent is a PBS buffer with a pH of 7.2-7.6.

[0039] For example, in S2, the concentration of Na2HPO4 in the fourth solvent is 8mM~12mM, the concentration of NaH2PO4 is 1.5mM~2mM, the concentration of potassium chloride is 2.5mM~3mM, and the concentration of sodium chloride is 0.12M~0.15M.

[0040] Preferably, in S2, the concentration of the Dictyostelium aurantium agglutinin solution is 1.5 mg / mL to 2 mg / mL.

[0041] Preferably, in S2, the solvent of the S-acetylthioacetic acid N-hydroxysuccinimide ester solution is a fifth solvent, and the fifth solvent is dimethyl sulfoxide.

[0042] Preferably, in S2, the concentration of the S-acetylthioacetic acid N-hydroxysuccinimide ester solution is 15mM~20mM.

[0043] Preferably, in S2, the molar ratio of the Dictyostelium aurantium lectin in the Dictyostelium aurantium lectin solution to the S-acetylthioglycolic acid N-hydroxysuccinimide ester in the S-acetylthioglycolic acid N-hydroxysuccinimide ester solution is 1:8-1:10.

[0044] The present invention can further improve the reaction rate of the amide reaction by controlling the above molar ratio, so that the reaction proceeds more thoroughly.

[0045] Preferably, in S2, the temperature of the amide reaction is 10°C to 35°C, and the time is 25min to 35min.

[0046] Preferably, in S2, the pH of the hydroxylamine hydrochloride solution is 7-7.5.

[0047] Preferably, in S2, the solvent of the hydroxylamine hydrochloride solution is a sixth solvent, and the sixth solvent is a PBS buffer containing 23 mM to 27 mM ethylenediaminetetraacetic acid.

[0048] Preferably, in S2, the volume molar ratio of hydroxylamine hydrochloride in the reaction solution and the hydroxylamine hydrochloride solution is 200 μL:0.45 mol to 200 μL:0.55 mol.

[0049] Preferably, in S2, the volume ratio of the reaction solution to the hydroxylamine hydrochloride solution is 9:1 to 11:1.

[0050] By limiting the above amount, the present invention can further improve the reaction rate of the deacetamide reaction and make the reaction proceed more thoroughly.

[0051] Preferably, in S2, the temperature of the deacetamidation reaction is 10°C to 35°C, and the time is 25min to 35min.

[0052] Preferably, S2 comprises the following preparation steps: S2-1, dissolving AAL in a fourth solvent to obtain an AAL solution; Dissolving SATA in a fifth solvent to obtain a SATA solution; Dissolve hydroxylamine hydrochloride in the sixth solvent, and adjust the pH to 7-7.5 with NaOH to obtain a hydroxylamine hydrochloride solution; S2-2, mixing the AAL solution and the SATA solution, performing an amide reaction, and obtaining an AAL-SATA solution; S2-3, mixing the AAL-SATA solution and the hydroxylamine hydrochloride solution, and performing a deacetamide reaction to obtain a thiolated Dictyostelium aurantium agglutinin solution.

[0053] Preferably, in S2-2, after the amide reaction is completed, ultrafiltration is required, and the filtrate is replaced 3 to 4 times, centrifuged, and the liquid is replaced to a fixed volume to obtain an AAL-SATA solution.

[0054] For example, in S2-2, a 10K ultrafiltration tube is used for ultrafiltration.

[0055] Further preferably, in S2-2, the solvent used for the liquid change is a PBS buffer with a pH of 7.2 to 7.5.

[0056] For example, in S2-2, the centrifugal temperature is 5°C to 10°C, the centrifugal time is 5 min to 10 min, and the centrifugal speed is 900 rpm to 1000 rpm.

[0057] Further preferably, in S2-2, the concentration of the AAL-SATA solution is 35 μM to 45 μM.

[0058] The invention is beneficial to the subsequent deacetamide reaction after the liquid is replaced by a specific solvent.

[0059] Preferably, in S2-3, after the deacetamidation reaction is completed, ultrafiltration is required, and the filtrate is replaced 3 to 4 times, centrifuged, and the liquid is replaced to a fixed volume to obtain an AAL-SH solution.

[0060] For example, in S2-3, a 10K ultrafiltration tube is used for ultrafiltration.

[0061] Further preferably, in S2-3, the solvent used for the liquid change is a PBS buffer containing 8 mM to 12 mM ethylenediaminetetraacetic acid.

[0062] For example, in S2-3, the centrifugal temperature is 5°C to 10°C, the centrifugal time is 5 min to 10 min, and the centrifugal speed is 900 rpm to 1000 rpm.

[0063] Further preferably, in S2-3, the concentration of the AAL-SH solution is 25 μM to 30 μM.

[0064] The invention is beneficial to the subsequent coupling reaction after the liquid is replaced by a specific solvent.

[0065] The present invention selects a specific fourth solvent, a fifth solvent, a sixth solvent and their content to improve the smooth progress of the amide reaction and the deacetamide reaction, and further improve the reaction rate. In the amide reaction, the succinimide group on SATA is removed, and AAL is labeled with SATA in the form of an amide bond; in the deacetamide reaction, hydroxylamine hydrochloride is used to remove acetamide, and the sulfhydryl group is exposed for use in the subsequent thiol-maleimide reaction to form a thioether bond.

[0066] Preferably, in S3, the mass ratio of mRNA@LNP in the mRNA@LNP solution to Dictyostelium aurantium lectin in the Dictyostelium aurantium lectin solution is 0.8:1 to 1.2:1.

[0067] Preferably, in S3, the coupling reaction is carried out at a temperature of 10°C to 35°C and for a time of 1.8h to 2.3h.

[0068] Preferably, in S3, after the coupling reaction is completed, it is necessary to keep the mixture at 2°C to 5°C overnight and purify it to obtain the nano drug delivery system for targeting the central nervous system through the nose and into the brain.

[0069] The present invention allows the coupling reaction to proceed more thoroughly by keeping the reaction at 2°C to 5°C overnight; the present invention has no special requirements for the purification step, and conventional methods in the art can be used.

[0070] In the present invention, the olefin structure in the maleimide group has a high reactivity, which allows the reaction between the thiol group and the maleimide to proceed without a catalyst in a highly polar solvent environment, such as water, dimethyl sulfoxide (DMSO), etc. (the chemical reaction occurs preferentially at a neutral pH), and the reaction rate between maleimide and thiol is relatively fast.

[0071] In a third aspect, the present invention provides an application of the above-mentioned nano drug delivery system for transnasal administration to the brain targeting the central nervous system or the nano drug delivery system for transnasal administration to the brain targeting the central nervous system prepared by the preparation method of the above-mentioned nano drug delivery system for transnasal administration to the brain targeting the central nervous system in drugs for treating or preventing degenerative diseases of the central nervous system.

[0072] Preferably, the drug is administered intranasally.

[0073] Preferably, the central nervous system degenerative disease includes Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease or amyotrophic lateral sclerosis.

[0074] The nano drug delivery system for central nervous system targeted via nasal delivery to the brain provided by the present invention can be widely used in the field of medicine for treating or preventing degenerative diseases of the central nervous system. All biological therapeutic agents that can target the cerebral cortex are suitable for the present invention, which provides a new idea for the preparation of new targeted drugs for nasal delivery to the brain and has broad application prospects in improving the delivery efficiency of nano drug delivery systems. BRIEF DESCRIPTION OF THE DRAWINGS

[0075] Figure 1 This is a particle size and light intensity distribution diagram of the nano drug delivery system for targeting the central nervous system via the nose to the brain in Example 1 of the present invention; Figure 2This is a Western blot of the expression of in vitro transcribed mRNA of mature BDNF modified by m1Pis in Application Example 1 of the present invention in Caco2 cells; wherein a represents a PBS blank control, b represents BDNF mRNA, c represents LNP, d represents EGFP mRNA@LNP, e represents a BDNF protein positive control, and f~k represent the translation expression of BDNF mRNA@LNP in Caco2 cells respectively; Figure 3 The expression of Dio-labeled Fluc mRNA@AAL / LNP and Fluc mRNA@LNP in Caco2 cells in Application Example 2 of the present invention; Figure 4 This is a bioluminescence image of wild-type ICR mice in Application Example 3 of the present invention; the drugs administered from left to right are PBS buffer, Fluc mRNA@LNP, Fluc mRNA@LNP, Fluc mRNA@AAL / LNP and Fluc mRNA@AAL / LNP; Figure 5 This is a schematic diagram of the preparation process of the Ai9 / Cre mRNA mouse model in Application Example 4 of the present invention; Figure 6 This is the fluorescence image of Cre mRNA@LNP in area E (hippocampus, hypothalamus) in Application Example 4 of the present invention; Figure 7 This is the fluorescence image of Cre mRNA@AAL / LNP in area E (hippocampus, hypothalamus) in Application Example 4 of the present invention. DETAILED DESCRIPTION

[0076] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0077] If no specific conditions are specified in the present invention, the conventional conditions or the conditions recommended by the manufacturer shall be followed; if no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.

[0078] In vitro transcription, capping, and methylation of mRNA for biotherapeutics involves the following steps: Sa, the coding sequence of the biotherapeutic drug is inserted into the pmRVac vector using the Gibson assembly method to generate a DNA template for in vitro transcription; the pmRVac vector contains a T7 promoter sequence, a 5'UTR, a 3'UTR, a 110nt segmented polyA and a SapI restriction enzyme site for transcription termination.

[0079] Sb, Cap1 mRNA was generated by T7 in vitro transcription followed by enzymatic capping and methylation.

[0080] To generate uncapped in vitro RNA transcripts, linear DNA template was mixed with T7 RNA polymerase, nucleotide triphosphates (NTPs), and a magnesium-containing buffer to set up an in vitro transcription reaction; the reaction mixture was Cap1 mRNA generated using the Vaccinia Capping System.

[0081] After denaturing the uncapped transcripts by heating, vaccinia capping enzyme, 2'-O methyltransferase, GTP, S-adenosylmethionine (SAM) and capping buffer were added to set up the capping reaction. The reaction mixture was incubated at 37°C for 1h; then the template DNA was removed by DNase I treatment and incubated at 37°C for 2h.

[0082] For the synthesis of m1Psi-modified transcripts, m1Psi was used instead of UTP for in vitro transcription.

[0083] Sc, capped transcripts were further purified using magnetic beads, and the isolated mRNA was eluted with acidic buffer and stored at -80°C. mRNA concentration and purity were measured on a UV-visible spectrophotometer; mRNA integrity was measured by denaturing agarose gel analysis; and mRNA molecules were identified using mRNA sequencing.

[0084] The mice used in the embodiments of the present invention are healthy male Ai9 mice, 4 to 6 weeks old, weighing about 15g to 20g, purchased from Guangzhou Bojin Biotechnology Co., Ltd., and the production unit license number is SYXK (Guangdong) 2023-0343. Wild-type ICR mice, 4 to 6 weeks old, weighing about 20 to 30g, were purchased from Guangzhou Bojin Biotechnology Co., Ltd., and the production unit license number is SYXK (Guangdong) 2023-0343. The animal experiments of the present invention have been reviewed and approved by the Yunzhou Biological Experiment Animal Welfare Committee, and the ethical review approval number is: BG-AMS-20240801LN01-Y.

[0085] In order to better illustrate the present invention, further examples are given below.

[0086] Example 1 This embodiment provides a nano drug delivery system for targeting the central nervous system through the nose and brain, and the preparation method thereof comprises the following steps: S1, Assembly of liposomal nanoparticles with biotherapeutic drugs: S1-1, first dissolve SM102, DSPC, cholesterol, DMG-pSar25 and DSPE-PEG-MAL in anhydrous ethanol respectively, and then mix the five mixed solutions evenly to obtain the first mixed system. The molar ratio of SM102, DSPC, cholesterol, DMG-pSar25 and DSPE-PEG-MAL is 50:10:38:1.5:0.5.

[0087] The biomacromolecule encoded by mRNA (BDNF mRNA) was dissolved in a sodium acetate solution with a pH of 4 and a concentration of 50 mM, and mixed evenly to obtain a second mixed system. The volume ratio of BDNF mRNA to sodium acetate solution was 1:1.

[0088] S1-2, adding the first mixed system and the second mixed system into a microfluidic mixer, wherein the molar ratio of the nitrogen element in the ionizable cationic lipid of the first mixed system to the phosphorus element in the mRNA of the second mixed system is 6:1; removing ethanol, dissolving in a solution containing 15 mM Tris-HCl and 15 mM sodium acetate, mixing evenly, and obtaining a BDNFmRNA@LNP solution with a concentration of 481 ng / μL.

[0089] S2, preparation of thiolated AAL: S2-1, dissolve 288 μg AAL in PBS buffer at pH=7.4, mix well, and obtain an AAL protein solution with a concentration of 1.8 mg / mL.

[0090] Dissolve SATA in DMSO and mix well to obtain a SATA solution with a concentration of 18 mM.

[0091] Dissolve 0.5 mol hydroxylamine hydrochloride in PBS buffer containing 25 mM EDTA, adjust the pH to 7.3 with NaOH, and obtain 20 μL hydroxylamine hydrochloride solution.

[0092] S2-2, the AAL protein solution and the SATA solution are mixed, the molar ratio of SATA in the SATA solution to AAL in the AAL protein solution is 9:1, and the amide reaction is carried out at room temperature for 30 minutes; after the reaction is completed, ultrafiltration is carried out, and the filtrate is exchanged with PBS buffer at pH = 7.3 for 3 to 4 times, centrifuged, and the volume is fixed to 200 μL with the above PBS buffer to obtain an AAL-SATA solution.

[0093] S2-3, the hydroxylamine hydrochloride solution and the AAL-SATA solution are mixed evenly, and the deacetamide reaction is carried out at room temperature for 30 minutes; after the reaction is completed, ultrafiltration is performed, and the filtrate is exchanged 3 to 4 times with a PBS buffer containing 10 mM EDTA, centrifuged, and the volume is fixed to 300 μL with the above PBS buffer to obtain an AAL-SH solution.

[0094] S3, Coupling of AAL-SH and BDNF mRNA@LNP: The BDNF mRNA@LNP solution and the AAL-SH solution were mixed, the mass ratio of BDNF mRNA@LNP in the BDNF mRNA@LNP solution and AAL used in the AAL-SH solution was 1:1, and the coupling reaction was carried out at room temperature for 2 hours, and then at 4°C overnight and purified to obtain a nano drug delivery system for intranasal administration to the brain targeting the central nervous system, which was recorded as BDNF mRNA@AAL / LNP.

[0095] The particle size analysis and morphology of BDNF mRNA@AAL / LNP were performed. The results are as follows: Figure 1 As shown. Figure 1 It can be seen that the median particle size of BDNF mRNA@AAL / LNP in this embodiment is 87.47 nm.

[0096] Example 2 This embodiment provides a nano drug delivery system for targeting the central nervous system through the nose and brain, and the preparation method thereof comprises the following steps: S1, Assembly of liposomal nanoparticles with biotherapeutic drugs: S1-1, first dissolve SM102, DSPC, cholesterol, DMG-pSar25 and DSPE-PEG-MAL in anhydrous ethanol respectively, and then mix the five mixed solutions evenly to obtain the first mixed system. The molar ratio of SM102, DSPC, cholesterol, DMG-pSar25 and DSPE-PEG-MAL is 48:12:38.3:1:0.7.

[0097] The biomacromolecule (Klotho mRNA) encoded by mRNA is dissolved in a sodium acetate solution with a pH of 3.5 and a concentration of 55 mM, and mixed evenly to obtain a second mixed system. The volume ratio of Klotho mRNA to the sodium acetate solution is 0.95:1.

[0098] S1-2, adding the first mixed system and the second mixed system into a microfluidic mixer, wherein the molar ratio of the nitrogen element in the ionizable cationic lipid of the first mixed system to the phosphorus element in the mRNA of the second mixed system is 5.2:1; removing ethanol, dissolving in a solution containing 12 mM Tris-HCl and 12 mM sodium acetate, mixing evenly, and obtaining a Klotho mRNA@LNP solution with a concentration of 500 ng / μL.

[0099] S2, preparation of thiolated AAL: S2-1, dissolve 290 μg AAL in PBS buffer at pH=7.2, mix well, and obtain an AAL protein solution with a concentration of 2 mg / mL.

[0100] Dissolve SATA in DMSO and mix well to obtain a SATA solution with a concentration of 20 mM.

[0101] Dissolve 0.55 mol of hydroxylamine hydrochloride in PBS buffer containing 25 mM EDTA, adjust the pH to 7.3 with NaOH, and obtain 21 μL of hydroxylamine hydrochloride solution.

[0102] S2-2, the AAL protein solution and the SATA solution are mixed, the molar ratio of SATA in the SATA solution to AAL in the AAL protein solution is 8:1, and the amide reaction is carried out at room temperature for 25 minutes; after the reaction is completed, ultrafiltration is carried out, and the filtrate is exchanged with PBS buffer at pH = 7.2 for 3 to 4 times, centrifuged, and the volume is fixed to 200 μL with the above PBS buffer to obtain AAL-SATA solution.

[0103] S2-3, the hydroxylamine hydrochloride solution and the AAL-SATA solution are mixed evenly, and the deacetamide reaction is carried out at room temperature for 25 minutes; after the reaction is completed, ultrafiltration is performed, and the filtrate is exchanged 3 to 4 times with a PBS buffer containing 8 mM EDTA, centrifuged, and the volume is adjusted to 300 μL with the above PBS buffer to obtain an AAL-SH solution.

[0104] S3, coupling of AAL-SH and Klotho mRNA@LNP: The Klotho mRNA@LNP solution and the AAL-SH solution were mixed, the mass ratio of Klotho mRNA@LNP to AAL used in the AAL-SH solution was 0.8:1, the coupling reaction was carried out at room temperature for 1.8 hours, then at 2°C overnight and purified to obtain a nano drug delivery system for transnasal administration to the brain targeting the central nervous system, which was recorded as Klotho mRNA@AAL / LNP.

[0105] Example 3 This embodiment provides a nano drug delivery system for targeting the central nervous system through the nose and brain, and the preparation method thereof comprises the following steps: S1, Assembly of liposomal nanoparticles with biotherapeutic drugs: S1-1, first dissolve SM102, DSPC, cholesterol, DMG-pSar25 and DSPE-PEG-MAL in anhydrous ethanol respectively, and then mix the five mixed solutions evenly to obtain the first mixed system. The molar ratio of SM102, DSPC, cholesterol, DMG-pSar25 and DSPE-PEG-MAL is 45:14:39:1.7:0.3.

[0106] The biomacromolecule (BDNF mRNA) encoded by mRNA was dissolved in a sodium acetate solution with a pH of 4.5 and a concentration of 45 mM, and mixed evenly to obtain a second mixed system. The volume ratio of BDNF mRNA to sodium acetate solution was 1.1:1.

[0107] S1-2, adding the first mixed system and the second mixed system into a microfluidic mixer, wherein the molar ratio of the nitrogen element in the ionizable cationic lipid of the first mixed system to the phosphorus element in the mRNA of the second mixed system is 6.8:1; removing ethanol, dissolving in a solution containing 18 mM Tris-HCl and 18 mM sodium acetate, mixing evenly, and obtaining a BDNFmRNA@LNP solution with a concentration of 450 ng / μL.

[0108] S2, preparation of thiolated AAL: S2-1, dissolve 288 μg AAL in PBS buffer at pH=7.6, mix well, and obtain an AAL protein solution with a concentration of 1.5 mg / mL.

[0109] Dissolve SATA in DMSO and mix well to obtain a SATA solution with a concentration of 15 mM.

[0110] Dissolve 0.45 mol hydroxylamine hydrochloride in PBS buffer containing 25 mM EDTA, adjust the pH to 7.3 with NaOH, and obtain 19 μL hydroxylamine hydrochloride solution.

[0111] S2-2, the AAL protein solution and the SATA solution were mixed, the molar ratio of SATA in the SATA solution to AAL in the AAL protein solution was 10:1, and the amide reaction was carried out at room temperature for 35 minutes; after the reaction, ultrafiltration was carried out, and the filtrate was exchanged with PBS buffer at pH = 7.5 for 3 to 4 times, centrifuged, and the volume was fixed to 200 μL with the above PBS buffer to obtain AAL-SATA solution.

[0112] S2-3, the hydroxylamine hydrochloride solution and the AAL-SATA solution are mixed evenly, and the deacetamide reaction is carried out at room temperature for 35 minutes; after the reaction is completed, ultrafiltration is performed, and the filtrate is exchanged 3 to 4 times with a PBS buffer containing 12 mM EDTA, centrifuged, and the volume is fixed to 300 μL with the above PBS buffer to obtain an AAL-SH solution.

[0113] S3, Coupling of AAL-SH and BDNF mRNA@LNP: The BDNF mRNA@LNP solution and the AAL-SH solution were mixed, the mass ratio of BDNF mRNA@LNP in the BDNF mRNA@LNP solution and AAL used in the AAL-SH solution was 1.2:1, and the coupling reaction was carried out at room temperature for 2.3 hours, then at 5°C overnight and purified to obtain a nano drug delivery system for intranasal administration to the brain targeting the central nervous system, which was recorded as BDNF mRNA@AAL / LNP.

[0114] Comparative Example 1 This comparative example provides a drug-loaded liposome nanoparticle (BDNF mRNA@LNP), the preparation method of which is similar to that of Example 1, except that DMG-pSar25 is replaced with an equal molar amount of DMG-PEG2000. The remaining steps are the same as S1 of Example 1 and will not be repeated.

[0115] The structural formula of DMG-PEG2000 is shown in Formula 5.

[0116]

[0117] Formula 5 Comparative Example 2 This comparative example provides a drug-loaded liposome nanoparticle (BDNF mRNA@LNP), the preparation method of which is similar to that of Example 1, except that DMG-pSar25 is replaced with an equal molar amount of ALC-0159 PEG. The remaining steps are the same as S1 of Example 1 and will not be repeated.

[0118] The structural formula of ALC-0159 PEG is shown in Formula 6.

[0119]

[0120] Formula 6 Comparative Example 3 This comparative example provides a drug-loaded liposome nanoparticle (BDNF mRNA@LNP), the preparation method of which is similar to that of Example 1, except that SM102 is replaced with an equal molar amount of ALC-0315. The remaining steps are the same as S1 of Example 1 and will not be repeated.

[0121] The structural formula of ALC-0315 is shown in Formula 7.

[0122]

[0123] Formula 7 The present invention uses a dynamic light scattering particle size analyzer (Zetasizer Ultra) to perform physical and chemical analysis on the BDNF mRNA@LNP provided in Examples 1 to 3 and Comparative Examples 1 to 3, and the results are shown in Table 1. PDI represents polymer dispersibility index.

[0124] Table 1 Physicochemical data of BDNF mRNA@LNP of Example 1 and Comparative Examples 1-3

[0125] The main function of PEG lipids is to stabilize and prolong the administration time of liposome nanoparticles by reducing protein binding interactions. However, the inventors found through a large number of experiments that repeated infusion of liposome nanoparticles will produce anti-PEG antibodies, resulting in the interaction between liposome nanoparticles and anti-PEG antibodies, accelerating blood clearance, thereby reducing the delivery efficiency of liposome nanoparticles; at the same time, anti-PEG antibodies can also produce severe allergic reactions. As can be seen from Table 1, DMG-PSar25 can completely replace DMG-PEG2000, and its use effect is better than that of liposome nanoparticles composed of DMG-PEG2000; the comprehensive effect of liposome nanoparticles compounded with SM102, DSPC, cholesterol and DMG-pSar25 is the best.

[0126] Application Example 1 Expression of BDNF mRNA in Caco2 mouse nasal mucosal cells In order to verify that mRNA@LNP can be converted into protein, the present invention transfected BDNF mRNA@LNP into Caco2 cells. The day before transfection, Caco2 cells were seeded in a 12-well plate at a seeding density of 2.2×10 5 cells / well. On the day of transfection, BDNF mRNA@LNP was added to the wells, and water was added to set up negative control wells. 24 hours after transfection, the cells were lysed in RIPA lysis buffer. The cell lysate was separated on a 4%~20% SDS-polyacrylamide gel and analyzed with a rabbit recombinant anti-BDNF monoclonal antibody. The results are shown in Figure 2 As shown. The results show that Figure 2 A 13.5kd band was shown, indicating the expression of BDNF, and the transfection amount of BDNF mRNA@LNP had a good correlation with the expression level of BDNF protein. Lane e was the positive control for BDNF protein, and lanes f~k were the translation expression of BDNF mRNA@LNP in Caco2 cells in a dose-dependent manner, which were 0.5μg, 1μg, 2μg, 0.5μg, 1μg and 2μg of BDNF mRNA@LNP, respectively; while no BDNF protein was detected in the cell lysates of BDNF mRNA (lane b), LNP (lane c) and EGFP mRNA@LNP (lane d).

[0127] Application Example 2 In vitro cellular uptake of a nanodrug delivery system targeting the central nervous system via the nose into the brain by Caco2 cells Caco2 cells are used to simulate the in vitro transport of olfactory epithelial cells to evaluate the uptake of nanodrug delivery systems that target the central nervous system through the nose and brain. Dio is a cell membrane green fluorescent probe used to label LNPs to track the uptake of LNPs by Caco2 cells. Dio was first dissolved in DMSO to make a 1mM~5mM storage solution; then dissolved and diluted with PBS buffer to make a 1μM~5μM working solution; the concentration of Dio was 1%. After Caco2 cells were treated with DiO-labeled LNPs for 2 hours, fluorescence imaging was performed, and the internalization of Dio-labeled LNPs by Caco2 cells was qualitatively observed by fluorescence microscopy imaging. The results are shown in the figure. Figure 3 The results showed that the fluorescence intensity of Fluc mRNA@AAL / LNP was significantly higher than that of Fluc mRNA@LNP.

[0128] The physical and chemical analysis of Dio-labeled Fluc mRNA@AAL / LNP and Fluc mRNA@LNP was performed using a dynamic light scattering particle size analyzer (Zetasizer Ultra). The results are shown in Table 2.

[0129] It should be noted that the preparation method of Fluc mRNA@AAL / LNP (and Fluc mRNA@LNP) is similar to that of Example 1, except that in S1-1, the biomacromolecule encoded by mRNA is replaced by luciferase (FlucmRNA) instead of BDNF mRNA, so as to facilitate the subsequent observation of fluorescence intensity and the analysis of the expression level of mRNA@LNP on cells. The remaining conditions are the same as those of Example 1 and will not be described in detail.

[0130] Table 2 Physicochemical data of Dio-labeled Fluc mRNA@AAL / LNP and Fluc mRNA@LNP

[0131] Application Example 3 Monitoring the expression of Fluc mRNA@AAL / LNP in mice via intranasal administration Fluc mRNA@AAL / LNP was centrifuged to remove unbound Fluc mRNA@LNP, and then 10 μg of drug was intranasally administered into the nasal cavity of wild-type ICR mice using a nanodrug delivery system targeting the central nervous system (PBS buffer, Fluc mRNA@LNP, and Fluc mRNA@AAL / LNP, respectively).

[0132] Before the experiment, the mice were anesthetized with isoflurane, and the next step was started after the breathing changed from shallow to deep. Before nasal drops, the mouse's head was turned up and placed on the mouse's mandible with the tip of the thumb. The thumb was kept away from the mouse's throat to avoid the swallowing reflex. After the mouse maintained a stable respiratory rhythm (and at the end of exhalation and the beginning of inhalation), the liquid was dripped into one nostril, one drop at a time. After nasal drops, moist rales can be heard in the mouse's lungs. The mouse was massaged to promote the redistribution of the liquid, kept on its back for 10 minutes, and finally put back in the cage. After 6 hours, the BLI signal was monitored and visualized using D-luciferin as a substrate. The results are shown as follows: Figure 4 The results showed that compared with Fluc mRNA@LNP, the BLI signal of Fluc mRNA@AAL / LNP was retained in the nostril for a longer time (more than 24 hours).

[0133] Application Example 4 Cross-sectional slices of mouse brain tissue Ai9 mice can stably express a fixed stop codon upstream of the tdTomato cassette, and tdTomato is only produced after the stop cassette is removed by Cre recombinase (circular recombinase). To evaluate the delivery efficiency of the nanodrug delivery system for intranasal delivery to the brain targeting the central nervous system, see Figure 5 , prepare Ai9 / Cre mRNA mouse model. If Cre mRNA@AAL / LNP delivered by nasal drip can be delivered into the brain and Cre is expressed in the brain, LoxP can be removed, thereby expressing red fluorescence.

[0134] It should be noted that the preparation method of Cre mRNA@AAL / LNP (and Cre mRNA@LNP) is similar to that of Example 2, except that in S1-1, the biomacromolecule encoded by mRNA is replaced by Cre mRNA instead of Klotho mRNA to facilitate the subsequent observation of red fluorescence. The remaining conditions are the same as those of Example 2 and will not be described in detail.

[0135] Ai9 mice were anesthetized by drugs and given nasal drops or sprays. The nasal drop volume of Cre mRNA@AAL / LNP was 10 μg (or 0.5 mg / kg). On the third day after administration (48 hours later), cross-sectional frozen sections of the mouse brain tissue were performed. The location of the brain tissue was the E area representing the hippocampus and hypothalamus of the brain. The tdTomato marker fluorescence expression was observed under a microscope. The results are as follows: Figure 6-7 As shown. Fluorescence imaging showed that compared with the PBS buffer and Cre mRNA@LNP control groups, the tdTomato fluorescence signal of all CremRNA@AAL / LNP groups was more robust and selective. The results confirmed that Cre recombinase mRNA was specifically expressed in the brain cells of mice after being injected into the brain through the nose, and strong expression of Tomato reporter fluorescence appeared in the brain, verifying that the nose-to-brain pathway was opened.

[0136] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A nano drug delivery system targeting the central nervous system through the nose and brain, characterized in that: It includes a biotherapeutic drug and a lectin-coupled liposome nanoparticle, wherein the lectin-coupled liposome nanoparticle is coated on the surface of the biotherapeutic drug; The biological therapeutic drug is a biological macromolecule encoded by mRNA; the lectin in the lectin-coupled liposome nanoparticles is a lectin from Dictyosporum aurantiacum, and the raw materials of the liposome nanoparticles include SM102, DSPC, cholesterol, DMG-pSar25 and phospholipid polyethylene glycol maleimide.

2. The nano drug delivery system targeting the central nervous system through the nose and into the brain as claimed in claim 1, characterized in that: The molar ratio of the SM102, the DSPC, the cholesterol, the DMG-pSar25 and the phospholipid polyethylene glycol maleimide is (45-50):(10-15):(38-40):(1-2):(0.3-0.7); The molar ratio of the nitrogen element in the ionizable cationic lipid of the liposome nanoparticle to the phosphorus element in the mRNA of the biotherapeutic drug is 4:1-8:

1.

3. The nano drug delivery system targeting the central nervous system through the nose and into the brain as claimed in claim 1, characterized in that: The mass ratio of the sum of the mass of the liposome nanoparticles and the biotherapeutic drug to the mass of the lectin is 0.8:1 to 1.2:1; The particle size of the nano drug delivery system for targeting the central nervous system through the nose and into the brain is 70nm-200nm.

4. The method for preparing the nano drug delivery system targeting the central nervous system through the nose into the brain according to any one of claims 1 to 3, characterized in that: The following steps are involved: S1, Assembly of liposomal nanoparticles with biotherapeutic drugs: S1-1, weighing each component according to the raw material ratio, dissolving SM102, DSPC, cholesterol, DMG-pSar25 and phospholipid polyethylene glycol maleimide in a first solvent to obtain a first mixed system; dissolving the biomacromolecule encoded by the mRNA in a second solvent to obtain a second mixed system; S1-2, adding the first mixed system and the second mixed system into a microfluidic mixer, removing the first solvent, and then dissolving in a third solvent to obtain an mRNA@LNP solution; S2, preparation of thiolated Dictyosporium aurantium agglutinin: The Dictyostelium aurantium agglutinin solution is mixed with the S-acetylthioacetic acid N-hydroxysuccinimide ester solution to carry out an amide reaction; the obtained reaction solution is mixed with the hydroxylamine hydrochloride solution to carry out a deacetamide reaction to obtain a thiolated Dictyostelium aurantium agglutinin solution; S3, coupling of thiolated Dictyosporium aurantium lectin with mRNA@LNP: The mRNA@LNP solution and the thiolated Dictyosporium aurantium lectin solution are mixed to carry out a coupling reaction, thereby obtaining a nano drug delivery system that targets the central nervous system through the nose and into the brain.

5. The method for preparing the nano drug delivery system targeting the central nervous system through the nose and brain as claimed in claim 4, characterized in that: In S1-1, the first solvent is ethanol; In S1-1, the second solvent is a sodium acetate solution with a pH of 3.5 to 4.5 and a concentration of 45 mM to 55 mM; In S1-2, the volume ratio of the first mixed system to the second mixed system is 1:2.5 to 1:3.5; In S1-2, the third solvent is a mixed solution of 12mM~18mM Tris-HCl and 12mM~18mM sodium acetate.

6. The method for preparing the nano drug delivery system targeting the central nervous system through the nose and into the brain as claimed in claim 4, characterized in that: In S2, the solvent of the Dictyostelium aurantium agglutinin solution is a PBS buffer solution with a pH of 7.2 to 7.5; In S2, the solvent of the S-acetylthioglycolic acid N-hydroxysuccinimide ester solution is dimethyl sulfoxide; In S2, the molar ratio of the Dictyostelium aurantium lectin in the Dictyostelium aurantium lectin solution to the S-acetylthioglycolic acid N-hydroxysuccinimide ester in the S-acetylthioglycolic acid N-hydroxysuccinimide ester solution is 1:8-1:

10.

7. The method for preparing the nano drug delivery system targeting the central nervous system through the nose and into the brain as claimed in claim 4, characterized in that: In S2, the solvent of the hydroxylamine hydrochloride solution is a PBS buffer containing 23mM~27mM ethylenediaminetetraacetic acid, and the pH of the hydroxylamine hydrochloride solution is 7~7.5; In S2, the volume molar ratio of hydroxylamine hydrochloride in the reaction solution and the hydroxylamine hydrochloride solution is 200 μL:0.45 mol to 200 μL:0.55 mol; In S2, the volume ratio of the reaction solution to the hydroxylamine hydrochloride solution is 9:1 to 11:1; In S3, the mass ratio of mRNA@LNP in the mRNA@LNP solution to Dictyostelium aurantium lectin in the Dictyostelium aurantium lectin solution is 0.8:1-1.2:

1.

8. The method for preparing the nano drug delivery system targeting the central nervous system through the nose and brain as claimed in claim 4, characterized in that: In S2, the temperature of the amide reaction is 10°C to 35°C, and the time is 25min to 35min; In S2, the temperature of the deacetamide reaction is 10°C to 35°C, and the time is 25min to 35min; In S3, the coupling reaction is carried out at a temperature of 10°C to 35°C and for a time of 1.8h to 2.3h.

9. Use of a nano drug delivery system for nasal administration to the brain targeting the central nervous system as claimed in any one of claims 1 to 3 or a nano drug delivery system for nasal administration to the brain targeting the central nervous system prepared by the preparation method of a nano drug delivery system for nasal administration to the brain targeting the central nervous system as claimed in any one of claims 4 to 9 in a drug for treating or preventing degenerative diseases of the central nervous system.

10. The use of the nano drug delivery system targeting the central nervous system through the nose to the brain as claimed in claim 9 in a drug for treating or preventing degenerative diseases of the central nervous system, characterized in that: The drug is administered intranasally.

Citation Information

Patent Citations

  • Pegylated lipid, liposome modified by pegylated lipid, pharmaceutical composition containing liposome, and preparation and application of pharmaceutical composition

    CN115197078A

  • Agglutinin-modified drug delivery system from nose to brain

    CN1839799A

  • Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery

    US6060082A

  • AU2007309727A1

Cited By

  • Nanosphere modified by lectin combined with targeting peptide as well as preparation method and application of nanosphere

    CN122097300A

  • Lectin combined with targeting peptide modified nanomicrospheres, and preparation method and application thereof

    CN122097300B